Treating autoimmune diseases

Yorkshire Photography

News: Latest – distributed around Yorkshire August 12, 2016 12:14:49 PM

New research from the University of Dundee, and funded by Arthritis Research UK and the MRC, has shown that targeting a specific group of enzymes could be a viable strategy for treating autoimmune diseases such as psoriasis and multiple sclerosis, which affect millions of people.

Autoimmune diseases develop when the immune system, which defends the body against disease, is convinced that our healthy cells are foreign. As a result, the immune system then attacks the healthy cells.

Researchers led by Dr Simon Arthur in the School of Life Sciences at Dundee examined the way that a drug called dimethylfumarate (DMF), which is licensed in the UK as Tecfidera, works. DMF is primarily used to treat multiple sclerosis but has also been shown to be an effective treatment for psoriasis, both of which are autoimmune diseases.

The team found that DMF is effective because it blocks the action of a particular group of enzymes called E2s, some of which are active in inducing inflammation.

“This is significant because previously the pharmaceutical industry has been sceptical lupus about the viability of targeting these enzymes as a means of treating diseases,” said Dr Vicky McGuire, lead author on the study.

“We have found that DMF is actually already targeting these enzymes with very positive results. This follows on from previous research from the University’s School of Life Sciences that showed that another drug, BAY 11-7082 also works by inhibiting E2 enzymes. However, unlike BAY 11-7082, DMF is approved for clinical use.”

Dr Arthur added, “This suggests that more selective inhibitors of E2’s may be well tolerated and validates these enzymes as targets for future drug development.”

Dr Stephen Simpson, director of research and programmes at the charity Arthritis Research UK, said he was excited by the results of the study they cofounded.

“Autoimmune conditions such as rheumatoid arthritis, lupus and psoriatic arthritis can have a devastating impact on people’s lives, causing extreme pain and fatigue that can make even everyday tasks incredibly difficult,” he said. “We welcome this research in helping identify pathways in these types of conditions that may offer targets for new and effective treatment”

The results of the research are published in Nature’s Scientific Reports.

Leave a Reply

The Cookie Law is a new piece of privacy legislation from Europe that requires websites to obtain consent from visitors to store or retrieve any information on a computer or any other web connected device. By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.


The Cookie law we are abiding by has been designed to protect online privacy, by making consumers aware of how information about them is collected by websites, and enable them to choose whether or not they want to allow it to take place.


It started as an EU Directive that was adopted by all EU countries on May 26th 2011. At the same time the UK updated its Privacy and Electronic Communications Regulations, which brought the EU Directive it into UK law.


Each EU member state has done or is doing the same thing. Although they all have their own approach and interpretation, the basic requirements of the directive remain the same.